Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain. …
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 Australian Biotech
Latest Video
New Stories
-
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News